Cargando…
Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer
BACKGROUND: Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for efficient anti-HER2 treatment of breast and gastric carcinomas. Immunohistochemistry (IHC) of the HER2 protein is the most common screening test, thus precise and reproducible IHC-scoring is of utmos...
Autores principales: | Scheel, Andreas H., Penault-Llorca, Frédérique, Hanna, Wedad, Baretton, Gustavo, Middel, Peter, Burchhardt, Judith, Hofmann, Manfred, Jasani, Bharat, Rüschoff, Josef |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848460/ https://www.ncbi.nlm.nih.gov/pubmed/29530054 http://dx.doi.org/10.1186/s13000-018-0696-x |
Ejemplares similares
-
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
por: van de Vijver, Marc, et al.
Publicado: (2007) -
HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
por: Rüschoff, Josef, et al.
Publicado: (2010) -
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status
por: Rüschoff, Josef, et al.
Publicado: (2022) -
Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
por: Cayre, Anne, et al.
Publicado: (2007) -
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
por: Styczen, Hanna, et al.
Publicado: (2015)